Quidelortho Corp (QDEL) Stock Price & Analysis
Quidelortho Corp (QDEL) fell 3.63% to USD 13.94 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
QDEL last closed at USD 14.47; the session ranged USD 13.68–15.16 on volume of 1,908,380 shares. Market capitalization is $950.58M, with a 52-week range of USD 9.92–35.58 (NMS). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 13.94 |
|---|---|
| Change | ▼ 3.63% (down) |
| Previous Close | USD 14.47 |
| Open | USD 14.59 |
| Day Range | USD 13.68 – 15.16 |
| 52-Week Range | USD 9.92 – 35.58 |
| Volume | 1,908,380 shares |
| Market Cap | $950.58M |
| Exchange | NMS |
Technical Analysis (QDEL)
Nexqual's technical model rates QDEL "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 58.53 (neutral) |
| vs SMA50 | Above (USD 13.08) |
| MACD | 0.44 (positive) |
Analyst Ratings (QDEL)
Wall Street analysts rate QDEL "None" based on 4 analysts, with a mean price target of USD 18.63 (range USD 11–38), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 18.63 |
| High Target | USD 38 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 1 / 3 / 1 |
Earnings (QDEL)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.01 |
| Revenue Estimate | $624.38M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est 0.36 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.42 ▲ beat |
| 2025-09-30 | USD 0.8 vs est 0.47 ▲ beat |
| 2025-06-30 | USD 0.12 vs est 0.01 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (QDEL)
| Total Revenue | $2.66B |
|---|---|
| Revenue Growth (YoY) | -10.50% |
| Gross Margin | +45.18% |
| Operating Margin | -4.10% |
| Profit Margin | -45.57% |
| ROE | -49.95% |
| Debt / Equity | 155.27 |
| Current Ratio | 1.43 |
| Total Cash | $140.40M |
| Total Debt | $2.87B |
| Free Cash Flow | $208.58M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (QDEL)
Nexqual rates Quidelortho Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 45%, operating -4% |
| Balance Sheet | Weak — $140M cash vs $2.87B debt |
| Cash Flow | Solid — FCF $209M, 8% margin |
| Efficiency | Critical — ROE -50%, ROA 0.5% |
Ownership (QDEL)
| Insider Ownership | +0.89% |
|---|---|
| Institutional Ownership | +124.04% |
| Shares Outstanding | 68.19M |
| Float | 62.12M |
| Short % of Float | +24.10% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (QDEL)
Quidelortho Corp is led by Brian J. Blaser (age 60), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| President, CEO & Director | Brian J. Blaser (age 60) |
|---|---|
| Chief Financial Officer | Joseph M. Busky (age 57) |
| Executive VP of Research & Development and CTO | Jonathan P. Siegrist (age 43) |
| Vice President of Investor Relations | Juliet C. Cunningham |
| Vice President of Global Marketing & Corporate Communications | Lisa S. Hayes |
Major Backers & Investors (QDEL)
Notable institutional backers of Quidelortho Corp include T. Rowe Price, FMR, LLC, American Century Companies Inc, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 10.42% |
| FMR, LLC | 9.67% |
| American Century Companies Inc | 7.92% |
| Fidelity | 6.73% |
| Newtyn Management, Llc | 6.68% |
| Rubric Capital Management LP | 4.85% |
| AIM Sector Funds (Invesco Sector Funds)-INVESCO SMALL CAP VALUE FUND | 4.66% |
| Invesco | 4.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.74% |
| Vanguard Group | 17.35% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Quidelortho Corp's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- QuidelOrtho Corporation provides diagnostic testing solutions.
- The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
- The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases.
- The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGEN | Repligen Corporation | USD 130.13 | ▲ 6.39% |
| FLGT | Fulgent Genetics, Inc. | USD 18.5 | ▼ 3.39% |
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
| NVCR | NovoCure Limited | USD 17.24 | ▲ 0.47% |
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.